Keyphrases
Positron Emission Tomography
100%
Radioligand
100%
5-HT2A Receptor Agonist
100%
Carbon-11
100%
Radiation Dosimetry
100%
Biodistribution
100%
Healthy Volunteers
66%
25B-NBOMe
66%
5-HT2A Receptor
33%
Receptor Binding
33%
Liver
33%
Toxic Effects
33%
Kidney
33%
Small Intestine
33%
Urinary Bladder
33%
Pancreas
33%
Whole-body
33%
Radiometabolism
33%
Fatal Outcome
33%
Gallbladder
33%
Metabolic Pathway
33%
Dosimetry
33%
Lowest Effective Dose
33%
International Guidelines
33%
Pharmacological Dose
33%
Standardized Uptake Value
33%
Severe Adverse Effects
33%
Time-activity Curve
33%
Metabolic Rate
33%
Effective Dose
33%
Single Subject
33%
Integrated Activities
33%
Recreational Drugs
33%
OLINDA
33%
Brown Adipose Tissue
33%
Non-labeled
33%
5-HT2C Receptor
33%
11C-labeling
33%
Excretory Organ
33%
Recreational Setting
33%
Value Curve
33%
Activity Coefficient
33%
Immunology and Microbiology
Positron Emission Tomography
100%
Agonist
100%
Normal Human
66%
Receptor Binding
33%
Pancreas
33%
Metabolite
33%
Metabolism
33%
Isotope Labeling
33%
Small Intestine
33%
Whole Body PET
33%
Metabolic Rate
33%
Brown Adipose Tissue
33%
Bladder
33%
Gallbladder
33%
Medicine and Dentistry
Receptor
100%
Carbon 11
100%
Dosimetry
100%
Biodistribution
100%
Positron Emission Tomography
27%
Radioligand
27%
Volunteer
18%
Adverse Event
9%
Metabolic Rate
9%
Bladder
9%
Fatality
9%
Receptor Binding
9%
Metabolite
9%
Metabolism
9%
Toxicity
9%
Small Intestine
9%
Standardized Uptake Value
9%
Brown Adipose Tissue
9%
Whole Body PET
9%
Recreational Drug
9%
Pharmacology, Toxicology and Pharmaceutical Science
Receptor Agonist
100%
Carbon 11
100%
Dosimetry
100%
Biodistribution
100%
Radioligand
27%
Receptor
18%
Normal Human
18%
Adverse Event
9%
Toxicity
9%
Fatality
9%
Recreational Drug
9%